For an older adult weighing peptide therapy, the repair and recovery category is where most practitioners start. Connective tissue, gut lining, and joint repair all draw on the same biological pathways, and the peptide roster in this category has the most-published rodent data and the cleanest early-human safety record of any peptide group outside the GLP-1 family.
The roster
Four peptides cover most of the work: BPC-157 for tendon, ligament, gut, and connective-tissue repair; TB-500 for systemic soft-tissue and muscle recovery; GHK-Cu for skin, hair, and gene-expression support; and KPV for gut inflammation in inflammatory bowel disease and leaky gut.
Each one has a distinct mechanism. BPC-157 is angiogenic and works through the nitric-oxide system. TB-500 (thymosin beta-4 fragment) works through actin sequestration and cell migration. GHK-Cu modulates four thousand-plus human genes at physiological concentrations. KPV is a three-amino-acid alpha-MSH fragment that acts through melanocortin receptor binding and NF-kB inhibition.
The dosing, briefly
BPC-157: 250 to 500 micrograms subcutaneously per day, 5 days on and 2 days off. TB-500: 2 to 2.5 milligrams twice weekly for a 4 to 6 week loading phase, then 2 milligrams every two weeks for maintenance. GHK-Cu injectable: 1 to 2 milligrams subcutaneously per day, in 30-day blocks with 30 days off. KPV: 200 to 500 milligrams orally per day, or 200 to 400 micrograms subcutaneously.
For full dosing, see the field reference entry for each peptide. For weight-adjusted dose ranges and a custom dose check, use the dosing calculator.
The timeline question
How long before you see results depends on the tissue. Gut epithelium shows measurable effects in 3 to 7 days. Skin and wound healing show effects in 1 to 2 weeks. Tendons and ligaments take 3 to 6 weeks for meaningful structural repair. Bone remodelling takes 4 to 8 weeks. Each tissue's baseline regenerative capacity is the primary determinant.
The rodent Achilles tendon transection data shows measurable differences between BPC-157-treated and control groups emerging at day 7, with the most significant structural and mechanical improvements at days 14 to 21. In humans, patient reports cluster around 3 to 6 weeks for noticeable pain reduction in chronic tendinopathy, and 8 to 16 weeks for full functional return. The user-reported timeline matches the rodent data when adjusted for species.
The honest case for BPC-157
BPC-157 has the strongest case in the category. Sikiric's group in Zagreb has run thirty years of work covering rat models of fistula, anastomosis, NSAID enteropathy, and tendon-to-bone healing. The Pliva human safety trials in inflammatory bowel disease showed a clean profile. The mechanism is coherent. The case is plausible, not proven.
What BPC-157 does not do: it does not regrow cartilage. It does not reverse severe osteoarthritis. It does not substitute for surgery in a failed joint replacement. It does not build muscle on its own. The realistic outcome is reduced pain, better function, and slower further degeneration in joints that still have biology left to work with.
The angiogenic question
The angiogenic peptides (BPC-157, TB-500, GHK-Cu) carry a theoretical concern about feeding tumour growth. The actual data is mixed. The conservative path is to avoid these classes in anyone with active cancer or a recent cancer history, and to discuss each one with an oncologist if there is a defined past history. The FDA's category 2 placement of BPC-157 in 2023 cited safety risk, though the agency's reasoning rested on the absence of human data rather than documented harm.
What this category cannot do
Peptides can support recovery, sleep, immune function, lean mass with training, and connective tissue repair. They cannot reverse sarcopenia on their own, reverse atherosclerosis, regrow cartilage, or substitute for the lifestyle factors that move the major age-related outcomes. The honest framing is that they are one tool in a stack of interventions, with the others being exercise, sleep, protein, cardiovascular risk control, social engagement, and the standard screening protocols.
Open questions for the prescriber
If you are weighing this category, the questions worth bringing to a prescriber are: which tissue is the priority, what is the realistic outcome, what blood work should I run before and during, what medication list do I need to disclose, and what does cycling look like over the next 6 to 12 months. The field reference and the FAQ have the rest.